News

Therapies aimed at correcting genes that cause diseases are gaining ground in biopharma, some are even specializing in specific mechanisms of action by targeting and modifying RNA through temporary and ongoing treatment. CEO at ProQR Therapeutics, Daniel de Boer, discusses how they are advancing RNA therapies in retinal disorders.

The latest industry happenings, all in one place.

More than 200 biopharma leaders acknowledge that out-of-pocket costs for individuals must be limited to sustain support for fiscal and patent policies key to advancing innovation.

An award made by the European Research Council allows Antonella Viola and her team at the University of Padova to be able to put funds into proof of concept work on using monoamine oxidase B inhibitors as novel drugs targeting NLRP3 inflammasome.